Abstract
Get full access to this article
View all access options for this article.
References
1.
Poseida Therapeutics. Poseida Therapeutics Announces Research Collaboration with Takeda for novel non-viral in vivo gene therapies
. October 12, 2021. https://investors.poseida.com/news-releases/news-release-details/poseida-therapeutics-announces-research-collaboration-takeda (last accessed
October 14 , 2021
).
2.
Selecta Biosciences. Selecta Biosciences announces strategic licensing agreement with Takeda to develop next-generation gene therapies for patients with lysosomal storage disorders
. October 4, 2021. https://ir.selectabio.com/news-releases/news-release-details/selecta-biosciences-announces-strategic-licensing-agreement (last accessed
October 14 , 2021
).
3.
Editas Medicine. Editas Medicine announces positive initial clinical data from ongoing phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 For LCA10
. September 29, 2021. https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-positive-initial-clinical-data-ongoing (last accessed
October 14 , 2021
).
4.
AbbVie and REGENXBIO. AbbVie and RE, GENXBIO Announce Eye Care Collaboration
. September 13, 2021. https://news.abbvie.com/news/press-releases/abbvie-and-regenxbio-announce-eye-care-collaboration.htm (last accessed
October 14 , 2021
).
5.
Voyager Therapeutics. Voyager therapeutics announces license option agreement with Pfizer for next-generation TRACER™ AAV capsids to enable neurologic and cardiovascular gene therapy programs
. October 6, 2021. https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-therapeutics-announces-license-option-agreement-pfizer (last accessed
October 14 , 2021
).
6.
Novartis
. Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss. September 21, 2021. https://www.novartis.com/news/media-releases/novartis-acquires-arctos-medical-expanding-optogenetics-portfolio-bring-gene-therapies-patients-severe-vision-loss (last accessed
October 14 , 2021
).
7.
CombiGene
. CombiGene and Spark Therapeutics enter exclusive, global licensing agreement for gene therapy candidate CG01. October 12, 2021. https://combigene.com/en/annual-reports-and-prospects/combigene-and-spark-therapeutics-enter-exclusive-global-licensing-agreement-for-gene-therapy-candidate-cg01 (last accessed
October 14 , 2021
).
8.
Intergalactic Therapeutics
. ATP unveils non-viral gene therapy innovator intergalactic therapeutics with $75 Million in Series A funding. October 7, 2021. https://www.prnewswire.com/news-releases/atp-unveils-non-viral-gene-therapy-innovator-intergalactic-therapeutics-with-75-million-in-series-a-funding-301394701.html (last accessed
October 14 , 2021
).